Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

Also called NCT04700436

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 146 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04700436
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04700436. Randomized; no masking; primary purpose treatment. Start 2020-01-03 (actual); primary completion 2021-05-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
Acronym
REMBRANDT
Condition
Endocrine System Diseases
Condition
Nutritional and Metabolic Diseases
Condition
Diabetes Mellitus, Type 2
Condition
Dyslipidemias
Intervention (Drug)
Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
Intervention (Drug)
Suvast tablet 10 mg (Rosuvastatin 10 mg)
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Gangnam Severance Hospital (class: other)

Record details

Record id
cardio:ct-nct04700436
Content hash
7d941adcf770f11a19e7d9f150dd2497a46cd0af495b42efa2b6f0f6c94f80d3